Literature DB >> 10860586

Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.

A Iliadis1, D Barbolosi.   

Abstract

In cancer chemotherapy, it is important to design treatment strategies that ensure a desired rate of tumor cell kill without unacceptable toxicity. To optimize treatment, we used a mathematical model describing the pharmacokinetics of anticancer drugs, antitumor efficacy, and drug toxicity. This model was associated with constraints on the allowed plasma concentrations, drug exposure, and leukopenia. Given a schedule of drug administrations, the mathematical model optimized the drug doses that can minimize the tumor burden while limiting toxicity at the level of the white blood cells. The main result is that the optimal drug administration is an initial high-dose chemotherapy up to saturation of constraints associated with normal cell toxicity and a maintenance continuous infusion at a moderate rate. Data related to etoposide investigations were used in a feasibility study. Simulations with the optimized protocol showed better performances than usual clinical protocols. Model-based optimal drug doses provide for greater cytoreduction, while limiting the risk of unacceptable toxicity. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860586     DOI: 10.1006/cbmr.2000.1540

Source DB:  PubMed          Journal:  Comput Biomed Res        ISSN: 0010-4809


  14 in total

Review 1.  Mechanistic models for myelosuppression.

Authors:  Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 2.  A review on numerical modeling for magnetic nanoparticle hyperthermia: Progress and challenges.

Authors:  Izaz Raouf; Salman Khalid; Asif Khan; Jaehun Lee; Heung Soo Kim; Min-Ho Kim
Journal:  J Therm Biol       Date:  2020-06-17       Impact factor: 2.902

3.  An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics.

Authors:  C Meille; A Iliadis; D Barbolosi; N Frances; G Freyer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-12-24       Impact factor: 2.745

4.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

5.  Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.

Authors:  Christophe Meille; Dominique Barbolosi; Joseph Ciccolini; Gilles Freyer; Athanassios Iliadis
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

6.  Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.

Authors:  Ron J Keizer; Y Funahashi; T Semba; J Wanders; J H Beijnen; J H M Schellens; A D R Huitema
Journal:  AAPS J       Date:  2011-03-09       Impact factor: 4.009

7.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

Review 8.  Computational oncology--mathematical modelling of drug regimens for precision medicine.

Authors:  Dominique Barbolosi; Joseph Ciccolini; Bruno Lacarelle; Fabrice Barlési; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

9.  Computational modeling of tumor response to vascular-targeting therapies--part I: validation.

Authors:  Jana L Gevertz
Journal:  Comput Math Methods Med       Date:  2011-03-23       Impact factor: 2.238

Review 10.  A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology.

Authors:  Kyungsoo Park
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.